EGFR and small cell lung carcinoma: Examples include amivantamab, targeting EGFR and MET fornon-small cell lung cancer; petosemtamab, targeting EGFR and LGR5 for head and neck squamouscell carcinoma; and izalontamab, which targets EGFR and HER3 for locally advanced ormetastatic epithelial tumors (Klein etal. 2024).